Peptide regulation and news

Start here

RegulatoryThe PCAC advisory committee: what it is and why it mattersRegulatoryThe 12 peptides removed from FDA restriction in 2026: what each one doesRegulatoryThe FDA 503A bulks list: how a peptide qualifies to be compoundedRegulatory10 questions to ask before buying any peptide onlineRegulatoryFDA boxed warning: the strongest label warning

All regulation & news guides (61)

• 10 questions to ask before buying any peptide online

  Is it safe to buy peptides online? Not without a prescription and a licensed pharmacy. Use these 10 questions to choose a peptide provider and spot red flags.

• 503A pharmacy regulations: the DQSA framework explained

  The DQSA defines what 503A pharmacies can and cannot compound. Here is the framework in plain English, why it exists, and what it means for peptide patients.

• AI-designed peptides: how computers invent new molecules

  AI tools like RFdiffusion can now design peptides that have never existed. Here's how computational protein design works and what it means for medicine.

• BPC-157 and the FDA: Category 2 status and what comes next

  BPC-157 was placed in FDA Category 2 in 2023 and removed in April 2026. FDA's advisory committee voted in July 2026 to recommend it for the 503A bulks list. Here is where things stand.

• BPC-157 in 2026: what changed, what hasn't, and what to expect

  BPC-157 status in 2026: FDA removed it from Category 2 in April, and FDA's advisory committee voted in July to recommend it for the 503A bulks list. FDA's final decision is pending.

• Category 1 vs Category 2 peptides: the access framework

  The FDA's Category 1 and Category 2 framework determines which peptides compounding pharmacies can legally prepare. Here's how it works.

• Category 2 peptides: what the access limits mean for patients

  What FDA Category 2 means for peptide access, where BPC-157 and TB-500 stand in 2026, and what patients should know.

• CJC-1295 regulatory and compounding status in 2026

  CJC-1295 is not FDA-approved. FDA removed it from Category 2 in September 2024. Here's what its regulatory status means for access in 2026.

• FAERS: how the FDA tracks drug side effects after approval

  FAERS is the FDA's adverse event reporting database for drugs on the market. See how reports come in, how to search them, and why a report is not proof.

• FDA accelerated approval pathway, explained

  FDA accelerated approval lets serious-disease drugs reach patients sooner using a surrogate endpoint, with confirmatory trials required after. Here's how.

• FDA boxed warning: the strongest label warning

  A boxed warning is the FDA's strongest drug label warning, shown in a box at the top. See when the FDA requires one and why it is information, not a verdict.

• FDA import alerts: why ordering peptides from overseas is risky

  FDA import alerts let inspectors detain products at the border. Here is what they mean for peptides ordered overseas and why the personal-use myth misleads.

• FDA orphan drug designation: rare-disease incentives

  FDA orphan drug designation gives rare-disease drug makers incentives like tax credits and 7 years of exclusivity. Here's what it is, and what it is not.

• FDA REMS: drug safety programs explained

  FDA REMS are drug safety programs for medications with serious risks. Here's what a REMS is, why the FDA requires one, and what it can include.

• FDA-approved peptide drugs vs gray-market peptides

  FDA-approved peptide drugs, compounded peptides, and gray-market peptides are three different things. Here is how to tell them apart, in plain English.

• FDA's March 2026 wave: 30 telehealth warning letters explained

  FDA sent ~30 warning letters to telehealth companies in March 2026 over compounded GLP-1 marketing. What was flagged, and what it means for patient access.

• How a peptide becomes a prescription medication

  How does a peptide go from a lab compound to a prescription medicine? Here is the path through research, trials, and approval, explained in plain English.

• How peptides came to be regulated: DQSA, FDCA, and compounding

  Peptide regulation traces to the FDCA, 1997 FDAMA, and 2013 DQSA, passed after a deadly 2012 meningitis outbreak at one U.S. compounding pharmacy.

• How the FDA categorizes peptides for 503A compounding

  The FDA sorts compounding-eligible peptides into Category 1 and Category 2. Here's how the sorting works, why it matters, and what changed in 2023, 2024, and 2026.

• How to Read an FDA Action Without the Headline Spin

  Does an FDA warning letter or guidance document actually ban a product? A plain-English guide to what FDA actions legally mean, before the headline spins it.

• IGF-1 LR3 Regulatory Status: Where It Actually Stands in 2026

  IGF-1 LR3 regulatory status in 2026: why it sits outside the standard 503A compounding framework, and what that means for legitimate access today.

• Ipamorelin Regulatory Status: Compounding Access in 2026

  Ipamorelin regulatory status in 2026: FDA removed it from 503A Category 2 in September 2024. It is not in any 503A category and is not on the 503A bulks list.

• Kisspeptin-10 Regulatory Status: Where It Actually Stands in 2026

  Kisspeptin-10 regulatory status in 2026: why it remains in FDA's 503A Category 2, and what that means for legitimate access.

• KPV Category 2 status: current compounding access explained

  KPV's regulatory status: removed from FDA Category 2 in April 2026 and not on the 503A bulks list. FDA's advisory committee voted to recommend it in July 2026.

• LegitScript and accreditation marks: what they actually certify

  What is LegitScript certification? A plain-English guide to what pharmacy accreditation marks like LegitScript and .pharmacy verify — and what they don't.

• MK-677 Regulatory Status in 2026

  MK-677 is not FDA-approved as a drug. As of September 2026, it is still in FDA's 503A Category 2. Here is where its regulatory status stands.

• MOTS-c Regulatory Status in 2026

  FDA removed MOTS-c from Category 2 in April 2026, and it is not on the 503A bulks list. Here is its current status and what could change it.

• NAD+ Regulatory Status: Compounding and Access in 2026

  Injectable NAD+ is not FDA-approved. It is compounded by 503A pharmacies, and the FDA is still evaluating NAD for its bulk drug substances list.

• Oxytocin: prescription status and compounded access

  Yes, oxytocin is prescription only. The injection is still a standard hospital drug for labor; the nasal spray sold for mood is a compounded prescription.

• PCAC July 2026 meeting: what the advisory committee is reviewing

  The FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026. Here is what the committee reviews, what it recommended, and what to watch.

• Peptide misinformation: the most repeated false claims of 2026

  The most repeated false claims about peptides circulating in 2026 — and what the FDA and Federal Register actually say. Calm, sourced, factual.

• PT-141 regulatory status in 2026: what is actually approved

  PT-141 (bremelanotide) is FDA-approved as Vyleesi for one specific indication. Compounded PT-141 is a different access path. Here is the 2026 regulatory picture in plain English.

• PT-141 regulatory status: FDA approval and compounding access

  PT-141 regulatory status: Vyleesi is FDA-approved for HSDD; compounded bremelanotide is prepared by 503A pharmacies. Access landscape in 2026.

• RFK Jr. and the Category 2 reversal: a clear timeline of what's actually happened

  A plain-English timeline of how FDA added 19 peptides to Category 2 in 2023 and removed 17 of them in 2024 and 2026. Compounded peptides are not FDA-approved.

• Secretary Kennedy's February 2026 peptide remarks, and what FDA did next

  In February 2026, HHS Secretary Kennedy said on a podcast that more peptides would become accessible. It was not a formal proposal. Here is what FDA actually did in April and July 2026.

• Selank regulatory status in 2026

  FDA removed Selank from Category 2 in September 2024. As of September 2026, it is in no FDA 503A category and is not on the 503A bulks list. Here is what that means.

• Semax regulatory status: Category 2 and the reclassification path

  Semax left FDA Category 2 in April 2026. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend it. FDA has not made a final decision.

• Sermorelin regulatory status and compounding access in 2026

  Sermorelin in 2026: from the FDA-approved Geref era to today's 503A compounding access, with the regulatory history and current rules in plain English.

• TB-500 regulatory status: Category 2 and the path forward

  TB-500 status in 2026: FDA removed it from Category 2 in April, and FDA's advisory committee voted in July to recommend it for the 503A bulks list. FDA's final decision is pending.

• Tesamorelin Regulatory Status: FDA Approval and Compounding Context

  Tesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy, but a compounded version is not FDA-approved. Here's what that distinction means.

• The 'banned overnight' myth: what actually happened to peptides in 2023

  The 2023 peptide story is told as a sudden ban. The actual story is slower and more procedural. Here is what really happened, in order, and why it matters.

• The 12 peptides removed from FDA restriction in 2026: what each one does

  The 12 peptides FDA removed from Category 2 on April 22, 2026, in plain English: a short reference to the compounds and what they do.

• The 2026 peptide regulatory landscape: a plain-English map

  The 2026 peptide regulatory landscape in plain English — Category 1 vs 2, the February 2026 Kennedy remarks, FDA's April 2026 list change, and the July 2026 PCAC votes.

• The FDA 503A bulks list: how a peptide qualifies to be compounded

  The 503A bulks list sets which raw ingredients compounding pharmacies may use. See the 3 ways one qualifies, how nominations work, and where peptides stand.

• The FDA Sentinel Initiative: drug safety after approval

  The FDA Sentinel Initiative actively monitors drug and vaccine safety after approval using health claims data — not voluntary reports. Here is how it works.

• The PCAC advisory committee: what it is and why it matters

  PCAC is the FDA's Pharmacy Compounding Advisory Committee. See how it votes on what 503A pharmacies may use and what it said about 7 peptides in July 2026.

• The PCAC: who decides which peptides are accessible

  The FDA's Pharmacy Compounding Advisory Committee (PCAC) advises FDA on which substances belong on the 503A bulks list. Here's how the process works and why it matters.

• The ProPublica peptide safety story: what it got right and wrong

  ProPublica raised real safety questions about compounded peptides. Here's what the reporting got right, where context was thin, and what patients should actually know.

• The RFK February 2026 peptide announcement: what it means

  In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. Here is what he said, what FDA did next, and what is still pending.

• The Ryan Haight Act and online prescribing: what it means for telehealth access

  The Ryan Haight Act sets the rules for prescribing controlled medications online. Here is what it is and why it shapes telehealth access in plain English.

• WADA prohibited peptides 2026: what's on the list and why

  WADA's 2026 prohibited list, explained. Which peptides are banned in tested sport, and what the Enhanced Games changes. Educational only.

• What FDA's PCAC briefing documents actually propose

  Before the July 23-24, 2026 meeting, FDA's briefing documents proposed that seven peptides not be added to the 503A Bulks List. The committee later voted to recommend six of them.

• What RFK Jr's Rogan interview actually said about peptide access vs. what the headlines claimed

  RFK Jr's Rogan appearance sparked headlines about peptides. Here's what he actually said, what it means for access, and what hasn't changed.

• What the April 2026 FDA peptide reclassification path actually means

  In April 2026, FDA removed 12 peptides from Category 2. Here is what changed, what FDA's July 2026 advisory committee recommended, and what is still pending.

• What the July 2026 PCAC meeting could change

  FDA's Pharmacy Compounding Advisory Committee met July 23–24, 2026, and reviewed seven peptides for the 503A bulks list. Here's what PCAC does, how it works, and what it recommended.

• Who actually makes compounded peptides? The supply chain

  Compounded peptides pass through API makers, CDMOs, and licensed pharmacies before reaching patients. Here is how the supply chain actually works.

• Who is affected by peptide regulatory changes and how

  Peptide regulatory changes ripple out to patients, prescribers, and pharmacies in different ways. Here is who is affected, how, and what each group can do next.

• Who is affected by the Category 1 vs 2 peptide framework

  The FDA's Category 1 vs Category 2 peptide framework shapes what compounding pharmacies can prepare. Here is who it affects and what it means.

• Why a prescription is a safety feature, not a hurdle

  A prescription is a safety check, not red tape. Here is what it verifies, why gray-market peptides skip it, and what the data say about online pharmacies.

• Why some peptides are still Category 2 after the 2026 reclassification news

  FDA removed 12 peptides from Category 2 in April 2026. MK-677 and kisspeptin-10 remain. Here is what has and has not actually moved.

• Why the 2023 peptide compounding ban happened: the FDA's rationale

  Why did the FDA restrict peptide compounding in 2023? A plain-English read of the Category 2 decisions and the agency's rationale at the time.